What you need to remember is that the current Anavex 2-73 trial is only a Ph 2a trial. A primary endpoint to the trial, which I believe is typical for most Ph 2a trials, is placing patients on different dosages to find out what the maximum tolerated dose is for patients that have different characteristics. For instance, maybe the trial will discover that the mild Alzheimers patients could tolerate a higher dose whereas the moderate patients could only tolerate a lower dose. Patients that dropped out due to dizziness etc..........probably were on too high a dose, given their particular circumstances.
The trial also seeks to correlate the different dosages with therapeutic effect. The trial has found that 14mg seems to be the minimum dose that gives some benefit.
Market Data 
Markets 
AI
